5,693 Shares in Johnson & Johnson $JNJ Purchased by Rydar Equities Inc.

Rydar Equities Inc. bought a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 5,693 shares of the company’s stock, valued at approximately $870,000.

Other hedge funds also recently modified their holdings of the company. W.H. Cornerstone Investments Inc. lifted its holdings in Johnson & Johnson by 0.7% in the second quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock valued at $1,206,000 after buying an additional 58 shares during the period. YANKCOM Partnership grew its holdings in Johnson & Johnson by 0.8% during the 2nd quarter. YANKCOM Partnership now owns 7,042 shares of the company’s stock worth $1,076,000 after acquiring an additional 58 shares during the period. Greenup Street Wealth Management LLC raised its position in shares of Johnson & Johnson by 3.1% during the 2nd quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock valued at $309,000 after acquiring an additional 60 shares during the last quarter. Ellis Investment Partners LLC lifted its stake in shares of Johnson & Johnson by 0.7% in the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock valued at $1,307,000 after purchasing an additional 62 shares during the period. Finally, Cypress Wealth Services LLC boosted its position in shares of Johnson & Johnson by 0.9% in the 2nd quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock worth $1,013,000 after purchasing an additional 62 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on JNJ shares. Raymond James Financial upped their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Stifel Nicolaus upped their price target on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Scotiabank began coverage on shares of Johnson & Johnson in a report on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 price objective for the company. Finally, Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $208.35.

Johnson & Johnson Trading Up 1.3%

NYSE:JNJ opened at $214.41 on Tuesday. The business’s 50-day simple moving average is $196.61 and its 200-day simple moving average is $177.85. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $215.19. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock has a market capitalization of $516.58 billion, a PE ratio of 20.70, a price-to-earnings-growth ratio of 2.36 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.